Clearmind Medicine (NASDAQ:CMND), a clinical-stage biopharmaceutical company focused on neuro-therapeutics, announced on Tuesday, April 14, 2026, that its lead oral candidate, CMND-100, successfully met the primary safety and tolerability endpoints in an FDA-approved Phase I/IIa dose-escalation trial.
The multinational, multicenter study was designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients suffering from Alcohol Use Disorder (AUD).
Data from the third and final cohort revealed a high safety profile, with no serious adverse events reported.
Crucially, the candidate maintained favorable tolerability even at the highest dose tested to date.
CMND-100 is based on MEAI (5-iodo-2-aminoindane), a non-hallucinogenic molecule that targets the neural pathways associated with binge behavior and alcohol cravings.
By interacting with the serotonergic and dopaminergic systems, the therapy aims to break the cycle of addiction without inducing the psychedelic effects typically associated with related compounds.
The successful completion of the dose-escalation portion of the study allows Clearmind to progress toward establishing a recommended Phase II dose.
The trial's results are particularly significant as they validate the potential of non-hallucinogenic psychedelic derivatives to serve as mainstream, orally administered treatments that do not require the intensive in-clinic supervision often mandated for hallucinogenic therapies.